CCL2 has been implicated in promoting breast cancer metastasis [74] as well as prostate cancer growth [75] while TREM1 expression in hepatic satellite cells negatively correlated with disease outcome and its expression was related to aggressive tumor behavior [76]. Here, CCL2 is linked to prostate carcinoma.